ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Libigel R&D cost meeting FDA SPA and Breast Cancer Analysis coudlnot have come from ANIP.

$6-$10 million to complete analysis of data collected up to Sept. 4th, 2012 according to Stephen Simes.

This does not include follow up examination for the full five year period regarding Breast Cancer and Cardiovascular safety.

The 3656 patients were to continue with yearly clinical office visits and have endometrial biopsies performed at baseline and at study years 1, 2, and 5.

With only 7300 patient years out of up to 18,820 patient years completed by Sept. 4th, 2012. That leaves 10,968 yearly office visits including 3656 endometrial biopsies plus the number of patients who still had not had their 2nd year where they were to have an endometrial biopsy.

Anip's R&D expenses for 2014, 2015 and first three quarters of 2016 totaled $8.323 million. This includes expenses related to their generic and specialty brand drugs including the Corti Drugs.

There is no way ANIP covered the bill. Logical choice is still Abbvie footing the bill for the added expenses.

JMHO